Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.
The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.
The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
Key benefits
The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
Key market segments
The world COPD and asthma drug market is segmented by medication class, disease and geography.
MARKET BY DISEASES
COPD
Asthma
MARKET BY MEDICATION CLASS
Combination Products
Seretide/Advair
Symbicort
Relvar/Breo Ellipta
Flutiform
Dulera
Others
Leukotriene Antagonists (LTA)
Singulair
Others
Inhaled Corticosteroids (ICS)
Qvar
Pulmicort
Aerospan
Flovent
Others
Anticholinergics
Spiriva
Others
Short Acting Beta Agonists(SABA)
ProAir
Ventolin
Others
Long Acting Beta Agonists (LABA)
Others
MARKET BY GEOGRAPHY
North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
KEY PLAYERS
GlaxoSmithKline (GSK)
Novartis AG.
Merck & Co.
Abbott Laboratories.
Boehringer Ingelheim.
AstraZeneca.
Roche Holding AG
Teva Pharmaceutical Industries.
Vectura Group
Pfizer
Other players in the value chain include (profiles not included in the report)
Mylan
Aerovance Inc.
Alkermes Inc.
Almirall SA
Genentech Inc.
Sepracor, Inc.
Skyepharma plc